FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022049673> ?p ?o ?g. }

• W2022049673 endingPage "3516" @default.
• W2022049673 startingPage "3502" @default.
• W2022049673 abstract "The inhibition of LTB4 binding to and activation of G-protein-coupled receptors BLT1 and BLT2 is the premise of a treatment for several inflammatory diseases. In a lead optimization effort starting with the leukotriene B4 (LTB4) receptor antagonist (2), members of a series of 3,5-diarylphenyl ethers were found to be highly potent inhibitors of LTB4 binding to BLT1 and BLT2 receptors, with varying levels of selectivity depending on the substitution. In addition, compounds 33 and 38 from this series have good in vitro ADME properties, good oral bioavailability, and efficacy after oral delivery in guinea pig LTB4 and nonhuman primate allergen challenge models. Further profiling in a rat non-GLP toxicity experiment provided the rationale for differentiation and selection of one compound (33) for clinical development." @default.
• W2022049673 created "2016-06-24" @default.
• W2022049673 creator A5012866478 @default.
• W2022049673 creator A5015327077 @default.
• W2022049673 creator A5015621532 @default.
• W2022049673 creator A5017460856 @default.
• W2022049673 creator A5018637502 @default.
• W2022049673 creator A5019225884 @default.
• W2022049673 creator A5020155270 @default.
• W2022049673 creator A5021551901 @default.
• W2022049673 creator A5026898712 @default.
• W2022049673 creator A5029032443 @default.
• W2022049673 creator A5030198642 @default.
• W2022049673 creator A5034921577 @default.
• W2022049673 creator A5035914285 @default.
• W2022049673 creator A5036340684 @default.
• W2022049673 creator A5036880050 @default.
• W2022049673 creator A5037732617 @default.
• W2022049673 creator A5039328891 @default.
• W2022049673 creator A5044751426 @default.
• W2022049673 creator A5049040465 @default.
• W2022049673 creator A5049716036 @default.
• W2022049673 creator A5053458339 @default.
• W2022049673 creator A5053887166 @default.
• W2022049673 creator A5054300531 @default.
• W2022049673 creator A5056756006 @default.
• W2022049673 creator A5057832661 @default.
• W2022049673 creator A5059332693 @default.
• W2022049673 creator A5060121074 @default.
• W2022049673 creator A5060602174 @default.
• W2022049673 creator A5062307716 @default.
• W2022049673 creator A5062796234 @default.
• W2022049673 creator A5066489417 @default.
• W2022049673 creator A5067696852 @default.
• W2022049673 creator A5069212303 @default.
• W2022049673 creator A5070441005 @default.
• W2022049673 creator A5073723435 @default.
• W2022049673 creator A5076750523 @default.
• W2022049673 creator A5078119352 @default.
• W2022049673 creator A5081247141 @default.
• W2022049673 creator A5084017953 @default.
• W2022049673 creator A5085950028 @default.
• W2022049673 creator A5086223067 @default.
• W2022049673 creator A5089798392 @default.
• W2022049673 date "2010-04-09" @default.
• W2022049673 modified "2023-10-01" @default.
• W2022049673 title "Discovery of Novel and Potent Leukotriene B₄ Receptor Antagonists. Part 1" @default.
• W2022049673 cites W1499768710 @default.
• W2022049673 cites W1569591709 @default.
• W2022049673 cites W1589202049 @default.
• W2022049673 cites W1979941665 @default.
• W2022049673 cites W1988900516 @default.
• W2022049673 cites W2001145791 @default.
• W2022049673 cites W2022764554 @default.
• W2022049673 cites W2024746405 @default.
• W2022049673 cites W2044864017 @default.
• W2022049673 cites W2049804385 @default.
• W2022049673 cites W2052134677 @default.
• W2022049673 cites W2052505697 @default.
• W2022049673 cites W2060598346 @default.
• W2022049673 cites W2062136031 @default.
• W2022049673 cites W2063274861 @default.
• W2022049673 cites W2090234567 @default.
• W2022049673 cites W2145702061 @default.
• W2022049673 cites W2150840665 @default.
• W2022049673 cites W2161976213 @default.
• W2022049673 cites W2249183791 @default.
• W2022049673 cites W2952757161 @default.
• W2022049673 doi "https://doi.org/10.1021/jm1001919" @default.
• W2022049673 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20380377" @default.
• W2022049673 hasPublicationYear "2010" @default.
• W2022049673 type Work @default.
• W2022049673 sameAs 2022049673 @default.
• W2022049673 citedByCount "10" @default.
• W2022049673 countsByYear W20220496732012 @default.
• W2022049673 countsByYear W20220496732013 @default.
• W2022049673 countsByYear W20220496732015 @default.
• W2022049673 countsByYear W20220496732016 @default.
• W2022049673 countsByYear W20220496732017 @default.
• W2022049673 countsByYear W20220496732018 @default.
• W2022049673 countsByYear W20220496732021 @default.
• W2022049673 countsByYear W20220496732022 @default.
• W2022049673 crossrefType "journal-article" @default.
• W2022049673 hasAuthorship W2022049673A5012866478 @default.
• W2022049673 hasAuthorship W2022049673A5015327077 @default.
• W2022049673 hasAuthorship W2022049673A5015621532 @default.
• W2022049673 hasAuthorship W2022049673A5017460856 @default.
• W2022049673 hasAuthorship W2022049673A5018637502 @default.
• W2022049673 hasAuthorship W2022049673A5019225884 @default.
• W2022049673 hasAuthorship W2022049673A5020155270 @default.
• W2022049673 hasAuthorship W2022049673A5021551901 @default.
• W2022049673 hasAuthorship W2022049673A5026898712 @default.
• W2022049673 hasAuthorship W2022049673A5029032443 @default.
• W2022049673 hasAuthorship W2022049673A5030198642 @default.
• W2022049673 hasAuthorship W2022049673A5034921577 @default.
• W2022049673 hasAuthorship W2022049673A5035914285 @default.
• W2022049673 hasAuthorship W2022049673A5036340684 @default.
• W2022049673 hasAuthorship W2022049673A5036880050 @default.

• next